Historie von Umsatz, Gewinn und Cashflow aus den offiziellen Geschäftsberichten.
The Cooper Companies, Inc., together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment offers spherical, toric, and multifocal contact lenses that address vision challenges, such as astigmatism, presbyopia, and myopia. Its CooperSurgical segment focuses on family and women's health care, which provides fertility products and services, medical devices, and contraception, as well as cryostorage, such as cord blood and cord tissue storage.
Interaktive Charts und vollständige Abschlüsse ansehen → Bewertungsmodell (DCF) →
| Gewinn- und Verlustrechnung | TTM → 2026-04-30 | 2025-10-31 | 2024-10-31 | 2023-10-31 | 2022-10-31 | 2021-10-31 | 2020-10-31 | 2019-10-31 | 2018-10-31 | 2017-10-31 | 2016-10-31 | 2015-10-31 | 2014-10-31 | 2013-10-31 | 2012-10-31 | 2011-10-31 | 2010-10-31 | 2009-10-31 | 2008-10-31 | 2007-10-31 | 2006-10-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gesamtumsatz | $4.2B | $4.1B | $3.9B | $3.6B | $3.3B | $2.9B | $2.4B | $2.7B | $2.5B | $2.1B | $2.0B | $1.8B | $1.7B | $1.6B | $1.4B | $1.3B | $1.2B | $1.1B | $1.1B | $951M | $859M |
| Bruttoergebnis | $2.7B | $2.5B | $2.6B | $2.4B | $2.1B | $2.0B | $1.5B | $1.8B | $1.6B | $1.4B | $1.2B | $1.1B | $1.1B | $1.0B | $924M | $805M | $677M | $596M | $610M | $520M | $526M |
| Bruttomarge % | 64.4% | 60.7% | 66.6% | 65.6% | 64.7% | 66.9% | 63.1% | 66.2% | 64.5% | 63.8% | 59.6% | 59.6% | 63.5% | 64.7% | 63.9% | 60.5% | 58.4% | 55.2% | 57.4% | 54.6% | 61.2% |
| Betriebsergebnis (EBIT) | $498M | $683M | $706M | $533M | $508M | $506M | $312M | $547M | $403M | $429M | $324M | $237M | $306M | $306M | $283M | $228M | $190M | $150M | $127M | $46M | $113M |
| Operative Marge % | 11.8% | 16.7% | 18.1% | 14.8% | 15.3% | 17.3% | 12.8% | 20.6% | 15.9% | 20.1% | 16.5% | 13.2% | 17.8% | 19.3% | 19.6% | 17.1% | 16.4% | 13.9% | 11.9% | 4.8% | 13.1% |
| Jahresüberschuss | $236M | $375M | $392M | $294M | $386M | $2.9B | $238M | $467M | $140M | $373M | $274M | $204M | $270M | $296M | $248M | $175M | $113M | $101M | $65M | ($11M) | $66M |
| Nettomarge % | 5.6% | 9.2% | 10.1% | 8.2% | 11.7% | 100.8% | 9.8% | 17.6% | 5.5% | 17.4% | 13.9% | 11.3% | 15.7% | 18.6% | 17.2% | 13.2% | 9.7% | 9.3% | 6.2% | -1.2% | 7.7% |
| EBITDA | $866M | $1.1B | $1.1B | $886M | $879M | $824M | $590M | $826M | $690M | $616M | $520M | $425M | $443M | $447M | $398M | $308M | $255M | $252M | $209M | $140M | $181M |
| Ergebnis je Aktie (EPS) | $1.18 | $1.87 | $1.96 | $1.48 | $1.94 | $14.77 | $1.20 | $2.33 | $0.70 | $1.88 | $1.40 | $1.03 | $1.38 | $1.49 | $1.26 | $0.91 | $0.61 | $0.55 | $0.35 | $-0.06 | $0.35 |
| Ausstehende Aktien (Mio.) | 195M | 200M | 200M | 199M | 199M | 199M | 198M | 200M | 199M | 198M | 196M | 197M | 196M | 199M | 197M | 193M | 186M | 182M | 187M | 179M | 190M |
Quelle: veröffentlichte Unternehmensberichte (SEC). Bitte prüfen Sie die Zahlen vor Verwendung auf SEC EDGAR.
Bilanzen, Cashflow-Rechnungen, Quartalsdaten und alle Kennzahlen finden Sie im interaktiven Viewer für COO. /companies/us/COO
Die Informationen auf dieser Website dienen ausschließlich Bildungs- und Informationszwecken und stellen keine Anlageberatung dar. Es werden keine Kursziele und keine Anlageurteile veröffentlicht.
About TickerBase · Data methodology & sources · Privacy · Terms